|
kim/ congrats on your doing so well on tdm1..
jean, roche/genentech has made public that they expect to file for approval for tdm1 in q1 / 2010 with an expected approval around q3-4 / 2010.
based upon results of the phase 2 tdm1 for patients who have progressed on tykerb. that study is considered as a 3rd line treatment, but once approved, docs will be lining up to prescribe it for those who need it, or whose insurance will cover.
|